Your browser doesn't support javascript.
loading
Potential role of CMPK1, SLC29A1, and TLE4 polymorphisms in gemcitabine-based chemotherapy in HER2-negative metastatic breast cancer patients: pharmacogenetic study results from the prospective randomized phase II study of eribulin plus gemcitabine versus paclitaxel plus gemcitabine (KCSG-BR-13-11).
Cho, E H; Kim, J-Y; Im, S-A; Jung, K H; Sohn, J; Lee, K S; Chae, Y S; Lee, K H; Kim, J H; Jang, J-H; Ahn, J H; Park, M S; Lee, S-Y; Park, Y H.
Afiliação
  • Cho EH; Department of Laboratory Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, South Korea.
  • Kim JY; Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
  • Im SA; Department of Internal Medicine, Seoul National University Hospital, Cancer Research Institute, College of Medicine, Seoul National University, Seoul, South Korea.
  • Jung KH; Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
  • Sohn J; Division of Medical Oncology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea.
  • Lee KS; Center for Breast Cancer, National Cancer Center, Goyang, South Korea.
  • Chae YS; Department of Internal Medicine, Kyungpook National University Hospital, Daegu, South Korea.
  • Lee KH; Department of Internal Medicine, Chungbuk National University Hospital, Cheongju, South Korea.
  • Kim JH; Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, South Korea.
  • Jang JH; Department of Laboratory Medicine and Genetics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
  • Ahn JH; Biomedical Statistics Center, Data Science Research Institute, Samsung Medical Center, Seoul, South Korea.
  • Park MS; Department of Statistics, Keimyung University, Daegu, South Korea.
  • Lee SY; Department of Laboratory Medicine and Genetics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea; Department of Clinical Pharmacology & Therapeutics, Samsung Medical Center, Seoul, South Korea; Department of Health Science and Technology, Samsung Advanced In
  • Park YH; Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea; Director of International Cooperation Committee, Korean Society of Medical Oncology, Seoul, South Korea. Electronic address: yhparkhmo@skku.edu.
ESMO Open ; 6(5): 100236, 2021 10.
Article em En | MEDLINE | ID: mdl-34438242
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama Tipo de estudo: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Female / Humans Idioma: En Revista: ESMO Open Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Coréia do Sul
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama Tipo de estudo: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Female / Humans Idioma: En Revista: ESMO Open Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Coréia do Sul